Global Blood Therapeutics Inc buy stratec
Summary
This prediction ended on 05.11.21 with a price of €33.71. With a performance of -7.61%, the BUY prediction by stratec finished with a loss. stratec has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Global Blood Therapeutics Inc | - | - | - | - |
iShares Core DAX® | -5.744% | -6.037% | 9.155% | 8.257% |
iShares Nasdaq 100 | -4.907% | -12.083% | 19.607% | 30.219% |
iShares Nikkei 225® | -7.230% | -10.182% | 3.445% | -1.121% |
iShares S&P 500 | -4.764% | -6.545% | 19.194% | 31.957% |
Comments by stratec for this prediction
In the thread Global Blood Therapeutics Inc diskutieren
stratec stimmt der Buy-Einschätzung von klostergang zu
stratec stimmt am 14.12.2017 der Buy-Einschätzung von klostergang mit dem Kursziel 42,5$ zu.
Überschrift: Global Blood Th., mit Produktentwicklung für SCD und Hypoxämie#
14.12.2017 Global Blood Therapeutics (NASDAQ:GBT) price raised to $70 (83% upside) from $51 by Needham citing expected positive results from the Phase 3 HOPE study of voxelotor in sickle cell disease.
The FDA granted the company's lead candidate voxelotor Breakthrough Therapy for the treatment of sickle cell disease. It has a similar designation in Europe. Voxelotor is an oral once-daily therapy that works by increasing hemoglobin's affinity for oxygen.
In the thread Trading Global Blood Therapeutics Inc